ATE301471T1 - Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation - Google Patents

Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation

Info

Publication number
ATE301471T1
ATE301471T1 AT97943316T AT97943316T ATE301471T1 AT E301471 T1 ATE301471 T1 AT E301471T1 AT 97943316 T AT97943316 T AT 97943316T AT 97943316 T AT97943316 T AT 97943316T AT E301471 T1 ATE301471 T1 AT E301471T1
Authority
AT
Austria
Prior art keywords
antibodies against
leukocyte antigen
immune modulation
against cd45ro
cd45ro leukocyte
Prior art date
Application number
AT97943316T
Other languages
German (de)
English (en)
Inventor
Andrew I Lazarovits
Sibrand Poppema
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE301471T1 publication Critical patent/ATE301471T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97943316T 1996-09-18 1997-09-17 Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation ATE301471T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/715,342 US6106834A (en) 1993-06-02 1996-09-18 Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
PCT/US1997/016321 WO1998011918A1 (en) 1996-09-18 1997-09-17 Use of antibodies to cd45r leukocyte antigens for immunomodulation

Publications (1)

Publication Number Publication Date
ATE301471T1 true ATE301471T1 (de) 2005-08-15

Family

ID=24873646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97943316T ATE301471T1 (de) 1996-09-18 1997-09-17 Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation

Country Status (8)

Country Link
US (3) US6106834A (enExample)
EP (1) EP0939652B1 (enExample)
JP (1) JP2001501607A (enExample)
AT (1) ATE301471T1 (enExample)
CA (1) CA2266684A1 (enExample)
DE (1) DE69733960T2 (enExample)
ES (1) ES2247638T3 (enExample)
WO (1) WO1998011918A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7014998B2 (en) 2000-09-30 2006-03-21 Yale University Screening immunomodulatory agents by CTLA-4 upregulation
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds
US20050069538A1 (en) * 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
WO2003048327A2 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
WO2003061695A1 (en) * 2002-01-17 2003-07-31 Amgen Inc. Methods of regulating cytokine receptor signaling
AU2003279657A1 (en) * 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
AU2003263043A1 (en) * 2002-08-28 2004-03-19 Sangstat Medical Corporation Methods and compostions for immune tolerance
US20040047858A1 (en) * 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
CA2535583A1 (en) * 2003-08-25 2005-03-03 Pangenetics B.V. Method of inducing immune tolerance
KR20060079232A (ko) * 2003-09-18 2006-07-05 노파르티스 아게 치료용 결합 분자
WO2007092196A2 (en) * 2006-01-27 2007-08-16 Cellerant Therapeutics, Inc. Compositions and methods for treating myeloid proliferative disorders
WO2007140457A2 (en) * 2006-05-31 2007-12-06 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
EP2789625B1 (en) 2006-08-18 2018-06-06 Argos Therapeutics, Inc. Use of soluble CD83 for perfusing a tissue for transplantation
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
EP2127671B1 (en) 2007-02-07 2016-09-14 Nec Corporation Therapeutic agent for cancer
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
US9713636B2 (en) 2011-02-28 2017-07-25 Napajen Pharma, Inc. Nucleic acid/polysaccharide complex
EP2742944B1 (en) * 2011-08-10 2018-06-27 Napajen Pharma, Inc. Immune tolerance inducer
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3174902B1 (en) * 2014-08-01 2019-04-17 Institut National de la Sante et de la Recherche Medicale (INSERM) An anti-cd45rc antibody for use as drug
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
HK1258726A1 (zh) 2015-09-28 2019-11-15 Regents Of The University Of Minnesota 嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
JP2019522050A (ja) 2016-06-17 2019-08-08 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 細胞の枯渇のための組成物および方法
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
US20190315878A1 (en) 2016-11-07 2019-10-17 Argos Therapeutics Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
US10576161B2 (en) 2017-01-20 2020-03-03 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
CA3128518A1 (en) * 2019-02-01 2020-08-06 Actinium Pharmaceuticals, Inc. Molecules and their derivatives directed against cd45
CN111707833A (zh) * 2020-06-19 2020-09-25 徐州医科大学 小鼠血管内外淋巴细胞识别的方法及其应用
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
CN116997654A (zh) 2021-03-17 2023-11-03 第一三共株式会社 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20230399375A1 (en) 2022-04-15 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
WO2023240064A1 (en) 2022-06-08 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
CN120554513B (zh) * 2025-07-28 2025-11-21 杭州华大生命科学研究院 一种抗cd45抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626507A (en) * 1980-09-25 1986-12-02 The Salk Institute For Biological Studies Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP0496806A1 (en) * 1989-10-20 1992-08-05 Lynxvale Limited Materials and methods for the treatment of foreign tissue
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
DK0606217T4 (da) * 1991-06-27 2009-03-30 Bristol Myers Squibb Co CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
GB9323542D0 (en) * 1993-11-15 1994-01-05 Univ Alberta Lymphocyte marker specific for corhn's disease
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US6174710B1 (en) 1994-08-09 2001-01-16 Pfizer Inc. Spirolaxine derivatives for treating gastrobuodenal diseases

Also Published As

Publication number Publication date
JP2001501607A (ja) 2001-02-06
EP0939652A1 (en) 1999-09-08
EP0939652B1 (en) 2005-08-10
CA2266684A1 (en) 1998-03-26
WO1998011918A1 (en) 1998-03-26
US6106834A (en) 2000-08-22
US7160987B2 (en) 2007-01-09
DE69733960D1 (de) 2005-09-15
US6379668B1 (en) 2002-04-30
ES2247638T3 (es) 2006-03-01
DE69733960T2 (de) 2006-05-24
US20020168362A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
FI961285A0 (fi) CD40:n vasta-aineita
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
NO950881L (no) Nöytraliserende monoklonale menneske-antistoffer mot respiratorisk syncytialt virus
DE69228556D1 (de) CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
NO965239D0 (no) Monoklonalt antistoff mot CD44v6
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
EP1003552A4 (en) ANTIBODIES DIRECTED AGAINST LO-CD2a AND USE THEREOF TO INHIBIT THE ACTIVATION AND PROLIFERATION OF T-LYMPHOCYTES
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
MX9706588A (es) Metodo para estimular una respuesta inmune.
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
DK0537168T3 (da) Antigenet CTAA 28A32, som genkendes af MCA 28A32
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
NO930406D0 (no) Spesifikke antistoffer mot aktiverte blodplater samt fremstilling
DE69010897D1 (de) Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin.
DE68924963D1 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0939652

Country of ref document: EP

REN Ceased due to non-payment of the annual fee